This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaminski, R. W.
Right arrow Articles by Oaks, E. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaminski, R. W.
Right arrow Articles by Oaks, E. V.

 Previous Article  |  Next Article 

Infection and Immunity, May 2006, p. 2856-2866, Vol. 74, No. 5
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.5.2856-2866.2006

Mucosal Adjuvant Properties of the Shigella Invasin Complex

Robert W. Kaminski, K. Ross Turbyfill, and Edwin V. Oaks*

Department of Enteric Infections, Division of Communicable Diseases and Immunology, The Walter Reed Army Institute of Research, Silver Spring, Maryland 20910

Received 14 November 2005/ Returned for modification 5 January 2006/ Accepted 18 February 2006

The Shigella invasin complex (Invaplex) is an effective mucosal vaccine capable of protecting against Shigella challenge in animal models. The major antigenic constituents of Invaplex are the Ipa proteins and lipopolysaccharide. The cell-binding capacity of the Ipa proteins prompted the investigation into the adjuvanticity of Invaplex. Using ovalbumin (OVA) as a model antigen, intranasal immunization with OVA combined with Invaplex was found to enhance anti-OVA serum immunoglobulin G (IgG) and IgA responses and induce OVA-specific mucosal antibody responses at sites located both proximal and distal to the immunization site. The immune responses induced with OVA and Invaplex were comparable in both magnitude and duration to the immune responses induced after immunization with OVA and cholera toxin. The OVA-specific immune response was characterized by high levels of serum IgG1 and increased production of interleukin-4 (IL-4), IL-5, or IL-10 from lymphoid cells of immunized animals, suggesting a Th2 response. In addition to enhancing the immunogenicity of OVA, Invaplex-specific immune responses were also induced, indicating the potential for the development of a combination vaccine consisting of Invaplex and other immunogens. Preexisting Invaplex-specific immunity did not interfere with the capacity to enhance the immunogenicity of a second, unrelated vaccine antigen, suggesting that Invaplex could be used as a mucosal adjuvant in multiple vaccine regimens.

* Corresponding author. Mailing address: Department of Enteric Infections, Division of Communicable Diseases and Immunology, The Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, MD 20910. Phone: (301) 319-9268. Fax: (301) 319-9801. E-mail: Edwin.oaks{at}na.amedd.army.mil.

Editor: J. T. Barbieri

Infection and Immunity, May 2006, p. 2856-2866, Vol. 74, No. 5
0019-9567/06/$08.00+0     doi:10.1128/IAI.74.5.2856-2866.2006




This article has been cited by other articles:

  • Kaminski, R. W., Turbyfill, K. R., Chao, C., Ching, W. M., Oaks, E. V. (2009). Mucosal Adjuvanticity of a Shigella Invasin Complex with DNA-Based Vaccines. CVI 16: 574-586 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»